Big pharma sits at the center of this dementia and brain health question.
Big Pharma is racing to develop psychedelic-based medicines because the mental health treatment landscape is failing millions of patients, and psychedelics represent the first genuinely novel mechanism of action in psychiatric medicine in decades. Unlike SSRIs and other daily medications that manage symptoms indefinitely, psychedelic compounds like psilocybin and MDMA have shown the potential to produce lasting therapeutic benefits from just one or a few doses — a paradigm shift that has Wall Street and pharmaceutical executives paying very close attention. The clearest signal came in August 2025, when AbbVie acquired Gilgamesh Pharmaceuticals’ lead psychedelic candidate, bretisilocin, for up to $1.2 billion — marking the first time a traditional Big Pharma company purchased an investigational psychedelic drug. This article explores the forces driving the pharmaceutical industry’s sudden pivot toward psychedelics, from landmark clinical trial results and a projected market worth up to $18.63 billion by 2035, to the regulatory signals coming out of Washington and the hard lessons learned from the FDA’s rejection of MDMA-assisted therapy.
For those of us who cover brain health and dementia care, these developments matter deeply. Depression, cognitive decline, and neuropsychiatric symptoms overlap significantly in aging populations, and any breakthrough in how we treat the brain’s serotonergic and neural plasticity pathways could have ripple effects well beyond the initial target conditions. The race is real, the money is enormous, and the science — while promising — is still navigating serious obstacles. Here is what you need to know.
Table of Contents
- What Sparked Big Pharma’s Sudden Interest in Psychedelic-Based Medicines?
- The FDA Pipeline — Which Psychedelic Drugs Are Closest to Approval?
- Why the MDMA Rejection Actually Strengthened the Psychedelic Medicine Movement
- How Psychedelic Medicines Differ from Traditional Psychiatric Drugs
- Regulatory and Political Winds — Who Is Helping and Who Is Hindering Progress?
- The Patent Race and What It Means for Patient Access
- What Psychedelic Medicine Could Mean for Brain Health and Dementia Care
- Conclusion
- Frequently Asked Questions
What Sparked Big Pharma’s Sudden Interest in Psychedelic-Based Medicines?
For years, psychedelic research was the domain of small biotech startups, nonprofits, and a handful of academic labs willing to work with compounds that carried decades of cultural stigma. The major pharmaceutical companies stayed away. What changed was a convergence of clinical evidence, commercial opportunity, and competitive pressure. Compass Pathways’ Phase 3 psilocybin trial announced statistically significant reductions in depression scores versus placebo in October 2025, and the company now expects a potential FDA approval decision in late 2026 or early 2027 — which would make it the first psilocybin therapy on the market. That kind of clinical milestone tends to get boardroom attention fast. AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals was the tipping point. It signaled to Wall Street that psychedelics were no longer a fringe bet but a legitimate pharmaceutical category.
The deal validated years of preclinical and early-stage work and spurred momentum for further mergers and acquisitions across the space. Meanwhile, Johnson & Johnson had already commercialized Spravato (esketamine), a psychedelic-adjacent drug for treatment-resistant depression, in January 2025 — proving that these kinds of therapies could navigate the regulatory process and generate revenue. The numbers tell the rest of the story. The global psychedelic drugs market was valued at approximately $4.08 to $4.78 billion in 2025 and is projected to reach $7.75 billion by 2030 at a compound annual growth rate of nearly 14 percent. Some estimates push the figure to $18.63 billion by 2035. Record venture funding for psychedelic therapies was reported in January 2026, and there are currently 82 active Phase II psychedelic trials globally, with 45 percent completed. When you combine that pipeline with an aging population facing unprecedented rates of depression, anxiety, and cognitive decline, it becomes clear why the big players decided they could no longer afford to sit this one out.
The FDA Pipeline — Which Psychedelic Drugs Are Closest to Approval?
The most advanced candidate is Compass Pathways’ synthetic psilocybin therapy for treatment-resistant depression. After hitting its primary endpoint in Phase 3, Compass plans to use a rolling submission process to get the drug before the FDA, potentially shaving 9 to 12 months off the timeline. If approved, it would be the first psilocybin-based therapy available through conventional medical channels — a historic first. The Usona Institute, a nonprofit, also announced the start of its own Phase 3 psilocybin trial in May 2025, which means there could be competing psilocybin products reaching the market within a few years of each other. Beyond psilocybin, Atai Life Sciences’ mebufotenin benzoate nasal spray received FDA Breakthrough Therapy Designation, a status that grants faster review and closer FDA collaboration. The drug is expected to enter Phase 3 trials in the first half of 2026.
Beckley Psytech’s intranasal 5-MeO-DMT for treatment-resistant depression is on a similar timeline. In total, five psychedelic biotech companies are now pushing toward Phase 3 for central nervous system treatments as of early 2026 — a critical mass that did not exist even two years ago. However, anyone watching this space should temper their expectations with a dose of realism. Phase 3 success does not guarantee FDA approval, as the MDMA story painfully demonstrated. The FDA issued a Complete Response Letter rejecting Lykos Therapeutics’ MDMA-assisted therapy for PTSD in August 2024, citing concerns about trial methodology. That rejection sent shockwaves through the industry and forced companies to redesign their approaches with more rigorous, cleaner trial protocols. If your main interest is in treatments for a loved one with dementia-related depression or agitation, the timeline from Phase 3 success to an actual prescription you can fill at a pharmacy is still measured in years, not months.
Why the MDMA Rejection Actually Strengthened the Psychedelic Medicine Movement
The FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD felt like a devastating blow in the fall of 2024. After years of advocacy and promising clinical data, the Complete Response Letter cited methodological concerns that called the trial results into question. Critics pointed to issues with blinding — it is extremely difficult to run a placebo-controlled trial when participants can easily tell whether they received a powerful psychoactive substance or a sugar pill. The rejection was a clear message from the FDA that psychedelic therapies would not get a pass on scientific rigor. But the setback redirected the industry in productive ways. Companies pivoted toward psilocybin and other compounds that lend themselves to cleaner trial designs.
Compass Pathways, for instance, used an active placebo approach and focused on measurable depression endpoints rather than subjective PTSD assessments. The MDMA failure also forced the industry to take the therapy component more seriously — you cannot just hand someone a powerful psychedelic compound and expect consistent outcomes without standardized therapeutic protocols. The companies that learned this lesson are now the ones closest to approval. For the brain health community specifically, this course correction is worth watching. Many of the neuropsychiatric symptoms associated with dementia — depression, anxiety, agitation, existential distress — overlap with the conditions that psychedelic therapies are being designed to treat. While no psychedelic is currently in clinical trials specifically for dementia-related symptoms, the mechanisms of action involving serotonin receptor activation and neural plasticity are directly relevant to neurodegenerative research.
How Psychedelic Medicines Differ from Traditional Psychiatric Drugs
The fundamental difference between psychedelic-based medicines and conventional psychiatric treatments is the dosing model. SSRIs, the current gold standard for depression, require daily use — often indefinitely — and come with a well-documented list of side effects including weight gain, sexual dysfunction, and emotional blunting. Roughly one-third of depression patients do not respond adequately to SSRIs at all. Psychedelic therapies, by contrast, aim to produce lasting benefits from one or a few guided sessions. Compass Pathways’ psilocybin protocol, for example, involves a single dose administered under clinical supervision, with therapeutic support before and after the session. This is an appealing model for several reasons, but it comes with real tradeoffs. The potential for a durable response from a limited number of doses could dramatically reduce the long-term cost and burden of treatment, particularly for elderly patients who already take multiple daily medications.
However, psychedelic sessions require hours of clinical supervision, specially trained therapists, and controlled settings — infrastructure that does not yet exist at scale. The cost per session could be substantial, and insurance coverage remains entirely uncertain. For patients in memory care facilities or those with advanced cognitive decline, the practical barriers to participating in a guided psychedelic session are significant and largely unaddressed. There is also the question of next-generation compounds. Companies are racing to patent modified psychedelic molecules that reduce trip duration or minimize hallucinations while preserving the therapeutic mechanism. AbbVie’s acquired compound, bretisilocin, is one such modified molecule. Whether stripping out the subjective psychedelic experience diminishes the therapeutic benefit is one of the most contested scientific questions in the field right now, and the answer will shape which products ultimately reach patients.
Regulatory and Political Winds — Who Is Helping and Who Is Hindering Progress?
The current political environment in the United States has created an unusual and somewhat unpredictable landscape for psychedelic medicine. RFK Jr. and FDA leadership have signaled openness to psychedelic therapies for mental health treatment under the Trump administration, creating what some observers see as a potentially favorable regulatory environment. This is a notable shift from the historically cautious FDA posture toward Schedule I substances, and it has energized both investors and advocates. But political enthusiasm does not replace scientific evidence, and there are reasons for caution.
Regulatory signals can change quickly with new appointments or shifting political priorities. The FDA’s rejection of MDMA therapy showed that the agency is willing to hold the line on methodological standards regardless of outside pressure, and there is no guarantee that a more sympathetic political environment will translate into faster approvals for compounds that have not met rigorous evidentiary thresholds. Patient access programs for psychedelic-assisted therapy are expanding in Germany, the Czech Republic, and Australia, which provides additional real-world data — but also highlights how far the United States still has to go in building the clinical infrastructure needed to deliver these treatments safely. For families dealing with dementia and related conditions, the regulatory picture adds another layer of uncertainty. Even if psilocybin receives FDA approval for treatment-resistant depression, prescribing it off-label for dementia-related neuropsychiatric symptoms would require physicians willing to navigate uncharted territory, and many will reasonably wait for condition-specific evidence before doing so.
The Patent Race and What It Means for Patient Access
One of the less visible but deeply consequential dynamics in psychedelic medicine is the patent race. Classic psychedelics like psilocybin and MDMA are old molecules that cannot be patented in their natural form. To build defensible commercial products, companies are creating modified versions — novel analogs, proprietary formulations, and unique delivery systems like nasal sprays — that qualify for patent protection and market exclusivity. Atai Life Sciences’ nasal mebufotenin benzoate and Beckley Psytech’s intranasal 5-MeO-DMT are both examples of this strategy.
The risk is that this approach could price patients out of treatments derived from compounds that grow in nature. If the only FDA-approved psilocybin product is a patented synthetic version administered in a proprietary clinical protocol, the cost structure may exclude the very populations who need it most — including elderly patients on fixed incomes and those in long-term care. On the other hand, patent protection is what motivates the billions of dollars in investment needed to run Phase 3 trials and navigate FDA approval. Without it, these compounds might never become approved medicines at all. It is a genuine tension with no easy resolution.
What Psychedelic Medicine Could Mean for Brain Health and Dementia Care
The intersection of psychedelic research and neurodegenerative disease is still in its earliest stages, but the scientific rationale is compelling. Psychedelics primarily act on serotonin 2A receptors and appear to promote neuroplasticity — the brain’s ability to form new neural connections. This mechanism is directly relevant to conditions involving neuronal loss and cognitive decline.
Early research in animal models has shown that psilocybin can stimulate dendritic growth and increase connectivity in brain regions affected by Alzheimer’s disease, though human clinical data specific to dementia remains extremely limited. Looking ahead, the current wave of Phase 3 trials focused on depression and PTSD will generate a wealth of safety and efficacy data that could eventually support trials in older adults with neurodegenerative conditions. With a projected $7.75 billion market by 2030 and five companies advancing toward Phase 3, the infrastructure and investment needed to explore these broader applications are falling into place. Whether psychedelics ultimately prove beneficial for dementia-related symptoms is a question that cannot be answered yet — but for the first time, the pharmaceutical industry has the financial incentive and scientific framework to seriously ask it.
Conclusion
The pharmaceutical industry’s pivot toward psychedelic medicine is driven by a straightforward calculus: existing psychiatric treatments fail too many patients, psychedelics offer a fundamentally different mechanism of action, and the commercial opportunity is enormous. AbbVie’s $1.2 billion bet on bretisilocin, Compass Pathways’ approaching FDA submission, and record venture funding in early 2026 all confirm that this is no longer a speculative movement. It is an emerging pharmaceutical category with real clinical data, real regulatory pathways, and real money behind it.
For those of us focused on brain health and dementia care, these developments warrant close but measured attention. The science of neural plasticity and serotonergic function connects psychedelic research directly to the challenges of neurodegeneration, even if specific dementia applications are years away. The most constructive posture right now is informed watchfulness — following the Phase 3 results as they come in, understanding the regulatory landscape, and recognizing both the genuine promise and the real limitations of where this field stands today.
Frequently Asked Questions
Are any psychedelic drugs currently FDA-approved?
No classic psychedelic has received full FDA approval yet. Johnson & Johnson’s Spravato (esketamine), a psychedelic-adjacent drug, was commercialized in January 2025 for treatment-resistant depression. Compass Pathways’ psilocybin therapy is the closest to potential approval, with a decision expected in late 2026 or early 2027.
Could psychedelics be used to treat dementia symptoms?
There are currently no clinical trials testing psychedelics specifically for dementia-related symptoms. However, the underlying mechanisms — serotonin receptor activation and promotion of neuroplasticity — are relevant to neurodegenerative conditions, and early animal research has been encouraging. Human trials for dementia applications are likely years away.
What happened with MDMA therapy for PTSD?
The FDA issued a Complete Response Letter rejecting Lykos Therapeutics’ MDMA-assisted therapy for PTSD in August 2024, citing concerns about trial methodology, including difficulties with blinding. The rejection redirected industry focus toward psilocybin and other compounds with cleaner trial designs.
How much does the psychedelic medicine market cost?
The global psychedelic drugs market was valued at approximately $4.08 to $4.78 billion in 2025 and is projected to grow to $7.75 billion by 2030 or as high as $18.63 billion by 2035, depending on the estimate.
Will insurance cover psychedelic therapy?
This remains entirely uncertain. Even after FDA approval, insurance coverage will depend on individual payer decisions, cost-effectiveness analyses, and the practical logistics of administering supervised psychedelic sessions. The requirement for hours of clinical supervision per session makes these therapies more expensive to deliver than a daily pill.
Are psychedelic therapies safe for older adults?
Safety data specific to older adults is very limited because most clinical trials have enrolled younger populations with depression or PTSD. Cardiovascular effects, drug interactions with existing medications, and the intensity of the psychedelic experience itself are all concerns that would need to be addressed in age-specific studies before these therapies could be broadly recommended for elderly patients.
You Might Also Like
- Why Doctors Are Now Cautious About This Prostate Drug
- The Pediatric Drug Recall That’s Affecting Millions of Parents Right Now
- The Allergy Drug Pediatricians Now Refuse to Prescribe for Young Kids
For more, see NIH MedlinePlus — dementia.
